www.mediafax.ro/externe/versiunea-ieftina-a-inject

The FDA has approved a generic version of lenacapavir, an injectable HIV prevention drug, making it accessible in 120 low- and middle-income countries at a cost of approximately $40 per year. This decision aims to enhance treatment access and reduce new infections among high-risk populations. The generic version, produced by Dr. Reddy’s Laboratories, was developed with support from international organizations. Lenacapavir requires only two injections per year, contrasting with daily pills, and has shown significant efficacy in clinical trials. However, it cannot be sold in the U.S. due to patent protections on the original drug, Yeztugo, which costs over $28,000 annually. The approval is seen as a crucial step towards expanding pre-exposure prophylaxis (PrEP) access globally, with potential to reach millions in need.